SHANGHAI, 12 octobre 2023 /PRNewswire/ — Shanghai Kehua Bio-engineering Co., Ltd (« KHB » ou « la société », code boursier : 002022.SZ), leader chinois du diagnostic in vitro (DIV), a franchi une étape importante en devenant la première société chinoise à obtenir la certification IVDR…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.